Bio

Peter Olagunju is a Cell & Gene Therapy executive, who has successfully worked to drive five C&GT products through clinical development to commercialization: PROVENGE, ZYNTEGLO, ABECMA, ADSTILADRIN, and SKYSONA. A diplomatic and tactful leader who excels in collaboration with colleagues at all levels. A strong proven track record in leading multiple departments and individuals while maintaining a high level of efficiency and quality. Peter is poised and competent with a demonstrated ability to easily unify departments company-wide. Peter is a versatile leader with the ability to maintain a strong sense of focus and guide others during periods of change and pressure. Peter thrives in deadline-driven environments and has excellent team-building skills. Specialties: -Management of Global Contract Manufacturers and Service Providers -Strategic Collaborations -Gene Therapy -Cellular Therapies - Internal Manufacturing Facility Builds -Technical Operations -Alliance Management -Monoclonal Antibody Protein Manufacturing -Lentiviral Vector Manufacturing -Technology Transfer -Contract Negotiation -Expertise in CMC/QA/Regulatory Compliance -FDA and EMEA Regulatory Submissions and Inspections -Economic and Financial Analysis